Skip to main content
Clinical Trials/DRKS00015267
DRKS00015267
Completed
Not Applicable

ong term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARIO

Merck KGaA0 sites1,115 target enrollmentAugust 29, 2018
ConditionsG35.9

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G35.9
Sponsor
Merck KGaA
Enrollment
1115
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 29, 2018
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Merck KGaA

Eligibility Criteria

Inclusion Criteria

  • Newly initiating oral cladribine or fingolimod according to local label for MS, after the date of oral cladribine launch in the relevant country.
  • \- Written informed consent is obtained:
  • \- at the date of oral cladribine or fingolimod treatment initiation or, at the latest, 24 weeks after oral cladribine or fingolimod treatment initiation in all countries for which primary data is used.
  • \- in those countries where secondary data collection is used and require an informed consent.

Exclusion Criteria

  • \- Received fingolimod prior to initiating oral cladribine;
  • \- Received oral cladribine prior to initiating fingolimod.

Outcomes

Primary Outcomes

Not specified

Similar Trials